A MLL-KIAA0284 fusion gene in a patient with secondary acute myeloid leukemia and t(11;14)(q23;q32)

Blood Cells, Molecules, and Diseases

Volumn 41, Issue 2, 2008, Pages 210-214

  Burmeister, Thomas ^a   Meyer, Claus ^b   Thiel, Gundula ^c   Reinhardt, Richard ^d   Thiel, Eckhard ^a   Marschalek, Rolf ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Praxis für Humangenetik Friedrichstrasse   (Germany)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

AML; Breast cancer; Chromosomal rearrangements; Cytogenetics of leukemia; DNA repair; MLL

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; MITOXANTRONE; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT CHEMOTHERAPY; ADULT; ANAMNESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME TRANSLOCATION; CODON; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUSION GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; INVERSE POLYMERASE CHAIN REACTION; LYMPHATIC SYSTEM DISEASE; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION;

BREAST NEOPLASMS; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS, SECOND PRIMARY; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 48749127542     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.05.005     Document Type: Article

References (34)

1. Meyer C., Schneider B., Jakob S., et al. The MLL recombinome of acute leukemias. Leukemia 20 (2006) 777-784
2. Shih L.Y., Liang D.C., Fu J.F., et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia 20 (2006) 218-223
3. Döhner K., Tobis K., Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J. Clin. Oncol. 20 (2002) 3254-3261
4. Jansen M.W., Corral L., van der Velden V.H., et al. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 21 (2007) 633-641
5. Libura J., Slater D.J., Felix C.A., and Richardson C. Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion. Blood 105 (2005) 2124-2131
6. Schoch C., Schnittger S., Klaus M., et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102 (2003) 2395-2402
7. Gleissner B., Gökbuget N., Rieder H., et al. CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood 106 (2005) 4054-4056
8. Burmeister T., Marschalek R., Schneider B., et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia 20 (2006) 451-457
9. Mailänder V., Scheibenbogen C., Thiel E., et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18 (2004) 165-166
10. Meyer C., Schneider B., Reichel M., et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 449-454
11. Beillard N., Pallisgaard N., van der Velden V.H., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17 (2003) 2474-2486
12. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 103 (1985) 620-625
13. Nilson I., Lochner K., Siegler G., et al. Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukaemias. Br. J. Haematol. 93 (1998) 966-972
14. Reichel M., Gillert E., Nilson I., et al. Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 17 (1998) 3035-3044
15. Marschalek R., Nilson I., Löchner K., et al. The structure of the human ALL-1/MLL/HRX gene. Leuk. Lymphoma 27 (1997) 417-428
16. Strissel P.L., Strick R., Rowley J.D., and Zeleznik-Le N.J. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 92 (1998) 3793-3803
17. Hensel J.P., Gillert E., Fey G.H., and Marschalek R. Breakpoints of t(4;11) translocations in the human MLL and AF4 genes in ALL patients are preferentially clustered outside of high-affinity matrix attachment regions. J. Cell. Biochem. 82 (2001) 299-309
18. Betti C.J., Villalobos M.J., Diaz M.O., and Vaughan A.T. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res. 61 (2001) 4550-4555
19. Betti C.J., Villalobos M.J., Jiang Q., et al. Cleavage of the MLL gene by activators of apoptosis is independent of topoisomerase II activity. Leukemia 19 (2005) 2289-2295
20. Scharf S., Zech J., Bursen A., Schraets D., et al. Transcription linked to recombination: a gene-internal promoter coincides with the recombination hot spot II of the human MLL gene. Oncogene 26 (2007) 1361-1371
21. Nasr F., Macintyre E., Venuat A.M., et al. Translocation t(4;11)(q21;q23) and MLL gene rearrangement in acute lymphoblastic leukemia secondary to anti topoisomerase II anticancer agents. Leuk. Lymphoma 25 (1997) 399-401
22. Aplan P.D. Chromosomal translocations involving the MLL gene: molecular mechanisms. DNA Repair 5 (2006) 1265-1272
23. Felix C.A., Hosler M.R., Slater D.J., et al. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J. Pediatr. Hematol. Oncol. 20 (1998) 299-308
24. Andersen M.K., Christiansen D.H., Jensen B.A., et al. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br. J. Haematol. 114 (2001) 539-543
25. Sim S.P., and Liu L.F. Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis. J.Biol. Chem. 276 (2001) 31590-31595
26. Khobta A., Carlo-Stella C., and Capranico G. Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene. Cancer Res. 64 (2004) 2656-2662
27. Campone M., Roché H., Kerbrat P., and Bonneterre J. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann. Oncol. 16 (2005) 1343-1351
28. Crump M., Tu D., Shepherd L., et al. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J.Clin. Oncol. 21 (2003) 3066-3071
29. Praga C., Bergh J., Bliss J., et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J. Clin. Oncol. 23 (2005) 4179-4191
30. Kröger N., Damon L., Zander A.R., et al. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplantation 32 (2003) 1153-1157
31. Strausberg R.L., Feingold E.A., Grouse L.H., et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16899-16903
32. Ota T., Suzuki Y., Nishikawa T., et al. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat. Genet. 36 (2004) 40-45
33. Heilig R., Eckenberg R., Petit J.L., et al. The DNA sequence and analysis of human chromosome 14. Nature 421 (2003) 601-607
34. Guarguaglini G., Duncan P.I., Stierhof Y.D., et al. The forkhead-associated domain protein Cep170 interacts with Polo-like kinase 1 and serves as a marker for mature centrioles. Mol. Biol. Cell 16 (2005) 1095-1107